[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335570-105":59,"doc-detail-335570-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-evolving-molecular-landscape-and-actionable-alterations-in-urologic-cancers","The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers","","The genetic landscape of urologic cancers has evolved alongside the discovery of actionable mutations that shape diagnosis, prognosis, and treatment planning. This narrative review synthesizes evidence on genetic mutations across bladder, renal, prostate, upper tract urothelial, testicular, and penile cancers, emphasizing DNA damage repair alterations (e.g., BRCA1/2, PTEN) and pathway dysregulation such as FGFR and PD-L1 overexpression. Molecular profiling using next-generation sequencing supports precision oncology, while emerging FGFR inhibitors and immune checkpoint blockade expand options despite ongoing resistance challenges. Biomarker identification remains critical for personalized management, especially in metastatic disease. Future research should clarify genomic drivers to enable novel individualized therapies and improve oncologic outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-evolving-molecular-landscape-and-actionable-alterations-in-urologic-cancers/335570/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-evolving-molecular-landscape-and-actionable-alterations-in-urologic-cancers/335570.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the focus of the review on urologic cancers?","Question",{"text":112,"@type":113},"The review consolidates how the genetic landscape of urologic cancers has evolved through actionable mutations that affect diagnosis, prognosis, and therapy selection across multiple cancer types.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which gene categories are highlighted as important in tumor behavior?",{"text":117,"@type":113},"The review emphasizes DNA damage repair and mismatch repair genes, along with tumor suppressors and pathway alterations such as BRCA1/2, PTEN, FGFR, and RB1, explaining how they contribute to genomic stability or dysregulation.",{"name":119,"@type":110,"acceptedAnswer":120},"How does molecular profiling influence patient care according to the document?",{"text":121,"@type":113},"It states that tools such as next-generation sequencing enable targeted treatment strategies, help define molecular subtypes, and support precision oncology decisions in clinical management, especially in metastatic settings.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335570,1790196502,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","Review  \nThe Evolving Molecular Landscape and Actionable Alterationsin Urologic Cancers  \nRyan Michael Antar *, Christopher Fawaz , Diego Gonzalez, Vincent Eric Xu , Arthur Pierre Drouaud ,  \nJason Krastein , Faozia Pio , Andeulazia Murdock , Kirolos Youssef, Stanislav Sobol and Michael J. Whalen   \nCitation: Antar, R.M.; Fawaz, C.; Gonzalez, D.; Xu, V.E.; Drouaud, A.P.; Krastein, J.; Pio, F.; Murdock, A.; Youssef, K.; Sobol, S.; et al. The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers. Curr. Oncol. 2024, 31, 6909–6937. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)curroncol31110511  \nReceived: 20 October 2024  \nRevised: 3 November 2024  \nAccepted: 4 November 2024  \nPublished: 6 November 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nDepartment of Urology, The George Washington University School of Medicine & Health Sciences, Washington, DC 20052, USA; [mwhalen@mfa.gwu.edu](mwhalen@mfa.gwu.edu) (M.J.W.)  \n* Correspondence: [ryanantar@gwu.edu](ryanantar@gwu.edu)  \nAbstract: The genetic landscape of urologic cancers has evolved with the identification of actionable mutations that impact diagnosis, prognosis, and therapeutic strategies. This narrative review consolidates existing literature on genetic mutations across key urologic cancers, including bladder, renal, prostate, upper tract urothelial, testicular, and penile. The review highlights mutations in DNA damage repair genes, such as BRCA1/2 and PTEN, as well as pathway alterations like FGFRand PD-L1 overexpression. These mutations influence tumor behavior and therapeutic outcomes, emphasizing the need for precision oncology approaches. Molecular profiling, through tools like next-generation sequencing, has revolutionized patient care by enabling targeted treatment strategies, especially in cancers with distinct molecular subtypes such as luminal or basal bladder cancer and clear cell renal carcinoma. Emerging therapies, including FGFR inhibitors and immune checkpoint blockade, offer new treatment avenues, although resistance mechanisms remain a challenge. We also emphasize the importance of biomarker identification for personalized management, especially in metastatic settings where treatment intensification is often required. Future research is needed to further elucidate our understanding of the genetics affecting urologic cancers, which will help develop novel, individualized therapies to enhance oncologic outcomes.  \nKeywords: urology; urologic cancers; genitourinary; prostate; bladder; renal cell carcinoma; testicular; penile; genetic mutations; molecular alterations  \n1. Introduction  \nCancer is a consequence of healthy cells undergoing cumulative mutations across singular or multiple genes, often over long periods of time. These series of mutations frequently confer a selective growth and survival advantage to the now abnormal cell, opening the door for further downstream mutations to foster uncontrolled growth [1] . These genetic mutations, therefore, underlie tumor behavior and have been linked to prognosis and response to therapy. Some genes are more potent in spurring abnormal cell growth and survival than others and can be referred to as “driver mutations”, implying their proliferative advantage. Other genes identified to be commonly mutated are the“passenger mutations”, which do not provide that same cell survival advantage [2] . Many such genes of each category have been identified since the dawn of the human genome project in 2004 . Among the common groups of cancer mutations are those involving DNA damage repair (DDR) genes, DNA mismatch repair (MMR) genes, PTEN, FGFR, and RB1 . D","cbCaiaAm6znuryTZ","https://ap.wps.com/l/cbCaiaAm6znuryTZ","pdf",405831,29,"English","# Introduction\n## Driver and passenger mutations\n## DNA damage repair and mismatch repair genes\n## Genomic instability, MSI, and immune checkpoint response\n## Key pathways and tumor suppressors (PTEN, FGFR, RB1)\n## TCGA and the shift toward bench-to-bedside decision-making","[{\"question\":\"What is the focus of the review on urologic cancers?\",\"answer\":\"The review consolidates how the genetic landscape of urologic cancers has evolved through actionable mutations that affect diagnosis, prognosis, and therapy selection across multiple cancer types.\"},{\"question\":\"Which gene categories are highlighted as important in tumor behavior?\",\"answer\":\"The review emphasizes DNA damage repair and mismatch repair genes, along with tumor suppressors and pathway alterations such as BRCA1/2, PTEN, FGFR, and RB1, explaining how they contribute to genomic stability or dysregulation.\"},{\"question\":\"How does molecular profiling influence patient care according to the document?\",\"answer\":\"It states that tools such as next-generation sequencing enable targeted treatment strategies, help define molecular subtypes, and support precision oncology decisions in clinical management, especially in metastatic settings.\"}]","The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers | PDF",1790011460,73]